NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

Jan 6, 2025 | Press Releases

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 — NAYA Biosciences (“NAYA”)...

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 31, 2024 | Press Releases

Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rateSARASOTA, Fla. and MIAMI, Oct. 31, 2024 — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

Oct 24, 2024 | Press Releases

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update...

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

Oct 21, 2024 | Press Releases

New Trading Symbol “NAYA” Effective Tuesday October 22, 2024SARASOTA, Fla. and MIAMI, Oct. 21, 2024 — INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and...

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

Oct 14, 2024 | Press Releases

Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseasesSARASOTA, Fla. and MIAMI, Oct. 14, 2024 — INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger...